Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Critical Therapeutics.

Request full access

Privately held biopharmaceutical company focused on critical care medicine

Lexington, United StatesFounded 2000Biotech & Life Sciences

About Critical Therapeutics.

Critical Therapeutics, Inc. was a biopharmaceutical company incorporated in Delaware on July 14, 2000, with a focus on developing and commercializing products for respiratory, inflammatory, and critical care diseases. The company's business strategy centered on regulating the body's inflammatory response. A significant part of their portfolio was built around zileuton, an active ingredient for which they acquired worldwide rights from Abbott Laboratories. In December 2003, the company licensed controlled-release and intravenous formulations of zileuton, and in March 2004, it licensed the immediate-release formulation and acquired the Zyflo® trademark.

The company's main commercial products were ZYFLO® (zileuton tablets) and its extended-release version, ZYFLO CR™. These were the only FDA-approved leukotriene synthesis inhibitors for the chronic treatment of asthma in adults and children 12 years and older. ZYFLO worked by blocking the 5-lipoxygenase enzyme, which is responsible for producing leukotrienes, a family of proteins that trigger asthma symptoms. Critical Therapeutics launched ZYFLO in the U.S. in October 2005, targeting allergy and respiratory specialists. A major milestone was the FDA approval of the twice-daily ZYFLO CR™ in May 2007, which was developed to improve patient compliance with a less frequent dosing schedule. The company managed its revenue generation by building a specialty sales force to market its products directly to healthcare providers. They also entered a co-promotion agreement with Dey, L.P. to expand their marketing reach.

In May 2008, Critical Therapeutics announced a definitive merger agreement with Cornerstone BioPharma Holdings, Inc., a privately-held specialty pharmaceutical company also focused on respiratory disorders. The stock-for-stock merger was completed in November 2008, resulting in former Cornerstone stockholders owning approximately 70% of the new entity and Critical Therapeutics stockholders owning about 30%. Following the merger, the combined company was renamed Cornerstone Therapeutics Inc. and continued to trade on NASDAQ under the ticker symbol "CRTX". This strategic move aimed to create a larger specialty pharmaceutical company with a more diversified product pipeline focused on respiratory diseases. Ultimately, Cornerstone Therapeutics was acquired by Chiesi Farmaceutici S.p.A. in 2014, marking the end of Critical Therapeutics' journey as an independent entity.

Source: Dealroom company data

At a glance

Status
Acquired
Open positions
None listed
Dealroom signal
17.7/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing May 2008 $0 — Cornerstone Therapeutics —
SERIES BOther financing Oct 2003 $56M $224M MedImmune Ventures · Johnson & Johnson Development Corporation · Advanced Technology Ventures · HealthCare Ventures —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Critical Therapeutics. website traffic

Latest recorded traffic for Critical Therapeutics. is 0 monthly website visits.

Latest monthly visits0
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Critical Therapeutics. in the Lexington ecosystem

Live from Dealroom

The Critical Therapeutics. office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

  • HealthCare Ventures
  • MPM BioImpact
  • Johnson & Johnson Development Corporation
  • Advanced Technology Ventures
  • MedImmune Ventures
  • Oxford Bioscience Partners

Other known investors1 additional known investor

  • Cornerstone Therapeutics
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Lexington HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Critical Therapeutics. on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Critical Therapeutics.’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.